Physician profile
Brian D Smith
NPI 1902803489
$8,360.23
in general payments reported to CMS, 2019-2025
55 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $949 · 2021: $1,460 · 2022: $1,401 · 2023: $1,193 · 2024: $1,244 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,748.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,011.62 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $790.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $608.35 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $568.53 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals Lp | $564.13 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $524.30 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $391.42 | 2022-2025 | |
| Pfizer INC. | $391.15 | 2019-2025 | |
| Amgen INC. | $282.47 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.65 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $258.17 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $210.42 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $189.35 | 2021-2024 | Spravato |
| Astellas Pharma US INC | $183.74 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $161.36 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.